Results 261 to 270 of about 52,371 (280)

Class struggle in DLBCL

Blood
Joanna A. Krupka, Daniel J. Hodson
openaire   +2 more sources

GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors

Cell Metabolism, 2019
Johanna Chiche, Sandrine Marchetti, Damien Ambrosetti   +2 more
exaly  

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

Annals of Oncology, 2018
Giovanna Motta, Fabio Mele, Stefano A Pileri   +2 more
exaly  

PAX5-activated lncRNA ARRDC1-AS1 accelerates the autophagy and progression of DLBCL through sponging miR-2355-5p to regulate ATG5

Life Sciences, 2021
exaly  

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

European Journal of Cancer, 2016
Ian W. Flinn, Nancy L Bartlett, Jonathan W Friedberg   +2 more
exaly  

Genetic alterations and their clinical implications in DLBCL

Nature Reviews Clinical Oncology, 2019
Leonard Jeffrey Medeiros, Yong Li, Ken H Young   +2 more
exaly  

Sweet stuff is dangerous in DLBCL

Blood
Falko Fend, Leticia Quintanilla-Martínez   +1 more
openaire   +2 more sources

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Annals of Oncology, 2018
Matthew J. Maurer, Raoul Herbrecht, Christopher R Flowers   +2 more
exaly  

Rituximab in DLBCL: 6 years on

The Lancet Oncology, 2011
openaire   +2 more sources

The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)†

Journal of Pathology, 2011
Rong Bu, Prashant Bavi, Shahab Uddin
exaly